Budding Multi-matrix Technology—a Retrospective Approach, Deep Insights, and Future Perspectives-Reference-Cited by-同舟云学术

Budding Multi-matrix Technology—a Retrospective Approach, Deep Insights, and Future Perspectives

Published:2021-11 Issue:8 Volume:22 Page:
ISSN:1530-9932
Container-title:AAPS PharmSciTech
language:en
Short-container-title:AAPS PharmSciTech

Author:

Sriram Anitha,Tangirala Suma,Atmakuri Srividya,Hoque Sajid,Modani Sheela,Srivastava Saurabh,Mahajan Srushti,Maji Indrani,Kumar Rahul,Khatri Dharmendra,Madan Jitender,Singh Pankaj Kumar

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmaceutical Science,Agronomy and Crop Science,Ecology,Aquatic Science,General Medicine,Ecology, Evolution, Behavior and Systematics

Link

https://link.springer.com/content/pdf/10.1208/s12249-021-02133-4.pdf

Reference214 articles.

1. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery–a review. Pharm Sci Technol Today. 2000;3(4):138–45.

2. Varma MV, et al. Factors affecting mechanism and kinetics of drug release from matrix-based oral controlled drug delivery systems. Am J Drug Deliv. 2004;2(1):43–57.

3. Tiwari SB, Rajabi-Siahboomi AR. Extended-release oral drug delivery technologies: monolithic matrix systems. Drug delivery systems. 2008;437:217–43.

4. Kotla N, Shivapooja A. Recent developments in colon specific drug delivery systems approaches promising in targeting colon. Int J Pharm Clin Res. 2014;6:101–6.

5. Grobman B. MULTIPLE MYELOMA PRESENTING AS CVA. Minerva Med. 1982;73(34):2183–8.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations;Digestive and Liver Disease;2024-09

2. Exploring Marine Rare Actinomycetes: Untapped Resources of Bioactive Compounds in Clinical Development;BIO Web of Conferences;2024

3. Management and treatment optimization of patients with mild to moderate ulcerative colitis;Expert Review of Clinical Immunology;2023-12-07

4. Chitosan functionalized PCL nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy;Pharmaceutical Development and Technology;2023-05-11

5. A Fully Replicate, Cross-over, Bioequivalence Study to Compare Two Prolonged Release, Multi-matrix Tablet Formulations of Budesonide in Healthy Indian Adults;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2023